超高剂量率质子FLASH改善肿瘤控制
研究在非小细胞肺癌(NSCLC)小鼠原位肺肿瘤模型中,比较常规质子治疗(CONVpr,<0.05 Gy/s)与超高剂量率质子FLASH治疗(FLASHpr,>60 Gy/s)的疗效。结果显示FLASHpr较CONVpr更有效减轻肿瘤负荷、抑制肿瘤细胞增殖,并增强细胞毒性CD8+ T淋巴细胞浸润、减少调节性T细胞(Tregs)比例、减少促肿瘤M2样巨噬细胞并增加抗肿瘤M1样巨噬细胞浸润;FLASHpr还降低肺肿瘤中检查点抑制剂表达,提示免疫耐受降低。作者认为FLASH剂量率质子递送可能通过调节免疫系统改善肿瘤控制,可能成为NSCLC治疗中有前景的新选择。
要点
- FLASHpr较CONVpr更有效减轻NSCLC小鼠原位肺肿瘤负荷并抑制肿瘤细胞增殖。
- FLASHpr增加肿瘤内细胞毒性CD8+ T淋巴细胞浸润,同时降低T淋巴细胞中免疫抑制性Tregs百分比。
- FLASHpr减少促肿瘤M2样巨噬细胞并增加抗肿瘤M1样巨噬细胞浸润,且降低肺肿瘤中检查点抑制剂表达。
核心结论
- 作者认为FLASH剂量率质子递送可能通过调节免疫系统改善肿瘤控制,并可能成为NSCLC治疗中替代常规剂量率的有前景新选择。
研究设计与样本
- 研究在NSCLC小鼠原位肺肿瘤模型中,比较常规质子治疗(CONVpr,<0.05 Gy/s)与超高剂量率质子FLASH治疗(FLASHpr,>60 Gy/s)的疗效。
主要发现
- 与CONVpr相比,FLASHpr在减轻肿瘤负荷和减少肿瘤细胞增殖方面更有效。
- FLASHpr较CONVpr更有效增加肿瘤内细胞毒性CD8+ T淋巴细胞浸润,同时降低T淋巴细胞中免疫抑制性调节性T细胞(Tregs)的百分比。
- 与CONVpr相比,FLASHpr更有效减少肺肿瘤中促肿瘤M2样巨噬细胞,同时增加抗肿瘤M1样巨噬细胞浸润。
- FLASHpr治疗降低肺肿瘤中检查点抑制剂表达,提示免疫耐受降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Proton radiotherapy (PRT) offers potential benefits over other radiation modalities, including photon and electron radiotherapy. Increasing the rate at which proton radiation is delivered may provide a therapeutic advantage. Here, we compared the efficacy of conventional proton therapy (CONVpr) to ultrahigh dose-rate proton therapy, FLASHpr, in a mouse model of non-small cell lung cancers (NSCLC). MATERIALS AND METHODS: Mice bearing orthotopic lung tumors received thoracic radiation therapy using CONVpr (<0.05 Gy/s) and FLASHpr (>60 Gy/s) dose rates. RESULTS: Compared to CONVpr, FLASHpr was more effective in reducing tumor burden and decreasing tumor cell proliferation. Furthermore, FLASHpr was more efficient in increasing the infiltration of cytotoxic CD8+ T-lymphocytes inside the tumor while simultaneously reducing the percentage of immunosuppressive regulatory T-cells (Tregs) among T-lymphocytes. Also, compared to CONVpr, FLASHpr was more effective in decreasing pro-tumorigenic M2-like macrophages in lung tumors, while increasing infiltration of anti-tumor M1-like macrophages. Finally, FLASHpr treatment reduced expression of checkpoint inhibitors in lung tumors, indicating reduced immune tolerance. CONCLUSIONS: Our results suggest that FLASH dose-rate proton delivery modulates the immune system to improve tumor control and might thus be a promising new alternative to conventional dose rates for NSCLC treatment.
引用
- Shukla S, Saha T, Rama N, et al. Ultra-high dose-rate proton FLASH improves tumor control. Radiother Oncol. 2023. PMID: 37315577. doi:10.1016/j.radonc.2023.109741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。